Printed From BioPortfolio.com

$ARVN Receives FDA clearance to Proceed for its IND Application for PROTAC™ Therapy to Treat Patients with Metastatic Castration-Resistant Prostate Cancer Expects Enrollment of Phase 1 Trial to Begin in Q1 2019

17:02 EST 4 Jan 2019 | Odi Bruckman

$ARVN Receives FDA clearance to Proceed for its IND Application for PROTAC™ Therapy to Treat Patients with Metastatic Castration-Resistant Prostate Cancer Expects Enrollment of Phase 1 Trial to Begin in Q1 2019

Original Article: $ARVN Receives FDA clearance to Proceed for its IND Application for PROTAC™ Therapy to Treat Patients with Metastatic Castration-Resistant Prostate Cancer Expects Enrollment of Phase 1 Trial to Begin in Q1 2019

More From BioPortfolio on "$ARVN Receives FDA clearance to Proceed for its IND Application for PROTAC™ Therapy to Treat Patients with Metastatic Castration-Resistant Prostate Cancer Expects Enrollment of Phase 1 Trial to Begin in Q1 2019"

Quick Links
Advanced Search | Login | Subscribe | RSS

Quick Search

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Prostate Cancer
Prostate cancer (cancer de prostata) Prostate cancer (cancer de prostata) is a form of cancer that develops in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, there are cases of aggressive prostat...

News Quicklinks

Search Biotech, Medical and Healthcare News

Biotech News by Article Type

BioPortfolio Bloggers

Publishing Your News on BioPortfolio

Recent Visitor News Searches